AdvanCell

Radiopharmaceutical company developing lead-212 targeted alpha therapies for cancer and building its own isotope manufacturing.

View on the globe

$315MEquity raised in 2025–20262025 — · 2026 $315M · 1 equity round
$315MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 15 Jul 2026 to 15 Jul 2026, $315M equity disclosed. Earlier rounds exist but are not sourced.15 Jul 2026: Series D, $315M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 20202026Q2Q3Q42027Q2Equity round15 Jul 2026 · Series D · $315M · led by Ally Bridge Group, Alpha Wave GlobalSeries D · $315M
Funding history: 1 round from 15 Jul 2026 to 15 Jul 2026, $315M equity disclosed. Earlier rounds exist but are not sourced.15 Jul 2026: Series D, $315M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’202026Q2Q3Q42027Q2Equity round15 Jul 2026 · Series D · $315M · led by Ally Bridge Group, Alpha Wave Global$315M

Funding history 1 round · 2 sources

Earlier rounds not yet sourced. AdvanCell was founded in 2020 and raised before 15 Jul 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series D
    Amount$315M
    Post-money—
    ✓ Confirmed
    Lead
    Ally Bridge Group, Alpha Wave Global
    Also
    Bain Capital Life Sciences, Fidelity, T. Rowe Price, Eventide Asset Management, Velosity Capital, Morningside, Eli Lilly, SV Health Investors, Sanofi, Abingworth, Brandon Capital, Catalio Capital Management
    Note
    Oversubscribed and upsized. Company release dated 15 July 2026; syndicated copies dated 16 July. Release also mentions a sovereign wealth fund (unnamed). Earlier rounds not sourced.
    Sources
  2. Earlier rounds not yet sourced

Investors 14

  • Ally Bridge Group1
  • Alpha Wave Global1
  • Abingworth
  • Bain Capital Life Sciences
  • Brandon Capital
  • Catalio Capital Management
  • Eli Lilly
  • Eventide Asset Management
  • Fidelity
  • Morningside
  • Sanofi
  • SV Health Investors
  • T. Rowe Price
  • Velosity Capital

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. AdvanCell and its logo are trademarks of their owners, used here for identification only.